Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen : to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

09/07/2021 | 05:22pm EDT

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi’s 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C. Wainwright Global Investment Conference being held on September 13-15, 2021.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually at Citi’s conference and Sanjay Subramanian, CFO and Head of Corporate Development will present virtually at H.C. Wainwright. Both will provide updates on COVAXIN™, the investigational COVID-19 vaccine which the company is co-developing with Bharat Biotech for the U.S. and Canadian markets. They will also present information about Ocugen’s breakthrough modifier gene therapy platform, which has generated product candidates that are expected to enter Phase 1/2a clinical trials in ophthalmic disease states over the next 18 months.

Citi/Ocugen Fireside Chat
Date/Time: Wednesday, September 8, 2021, from 3:15PM-4:00PM Eastern Time
Registration link: https://kvgo.com/citi-16th-annual-biopharma-vc/ocugen-inc-sept-2021

H.C. Wainwright Global Investment Conference
Date/Time: Presentation available on-demand starting at 7:00AM Eastern Time on September 13, 2021
Registration link: https://journey.ct.events/view/705764c5-88a7-4a4c-afff-d1688de5a5d9

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com. 

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as risks and uncertainties regarding market and other conditions and the timing of our planned clinical trials. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. 

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications

Primary Logo

Source: Ocugen

2021 GlobeNewswire, Inc., source Press Releases

All news about OCUGEN, INC.
10/16OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/15INSIDER SELL : Ocugen
10/15OCUGEN : Thinking about buying stock in Plug Power, Cemtrex, Ocugen, NRX Pharmaceuticals, ..
10/14SOCIAL BUZZ : Ocugen, AMC, BlackBerry Top WallstreetBets Stock Gainers at Thursday Close
10/14SOCIAL BUZZ : BlackBerry Seeing Late Day Strength
10/13SOCIAL BUZZ : Plug Power Surges, Ocugen Slides
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
10/12SOCIAL BUZZ : Wallstreetbets Top Stocks Ocugen, SoFi, Tesla Gain as Broader Market Slides
10/12SOCIAL BUZZ : Ocugen Bulls Pushing Shares to Fresh Highs Late
10/12OCUGEN : Thinking about buying stock in Ocugen, aTyr Pharma, Nextplay Technologies, Aerie ..
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -30,2x
Yield 2021 -
Capitalization 1 721 M 1 721 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 12,7x
Nbr of Employees 15
Free-Float 97,5%
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 8,66 $
Average target price 7,90 $
Spread / Average Target -8,78%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.373.22%1 721
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414